Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Desmond Tutu HIV Centre
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies
CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies, and more
Commentary from Dr. Kenneth Mayer on data from HIVR4P 2021 on immunoprophylaxis and multipurpose prevention as PrEP, from Clinical Care Options (CCO)
Expert selections of the most important data from HIVR4P 2021 Virtual, including PrEP clinical trials, implementation strategies and more, from CCO